A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1.
Numata, M., Haginoya, N., Shiroishi, M., Hirata, T., Sato-Otsubo, A., Yoshikawa, K., Takata, Y., Nagase, R., Kashimoto, Y., Suzuki, M., Schulte, N., Polier, G., Kurimoto, A., Tomoe, Y., Toyota, A., Yoneyama, T., Imai, E., Watanabe, K., Hamada, T., Kanada, R., Watanabe, J., Kagoshima, Y., Tokumaru, E., Murata, K., Baba, T., Shinozaki, T., Ohtsuka, M., Goto, K., Karibe, T., Deguchi, T., Gocho, Y., Yoshida, M., Tomizawa, D., Kato, M., Tsutsumi, S., Kitagawa, M., Abe, Y.(2023) Cancer Cell Int 23: 36-36
- PubMed: 36841758 
- DOI: https://doi.org/10.1186/s12935-023-02877-y
- Primary Citation of Related Structures:  
8IG0 - PubMed Abstract: 
Mixed lineage leukemia 1-rearranged (MLL1-r) acute leukemia patients respond poorly to currently available treatments and there is a need to develop more effective therapies directly disrupting the Menin‒MLL1 complex. Small-molecule-mediated inhibition of the protein‒protein interaction between Menin and MLL1 fusion proteins is a potential therapeutic strategy for patients with MLL1-r or mutated-nucleophosmin 1 (NPM1c) acute leukemia ...